Literature DB >> 33484937

Thalamic, Amygdalar, and hippocampal nuclei morphology and their trajectories in first episode psychosis: A preliminary longitudinal study.

Dung Hoang1, Paulo Lizano2, Olivia Lutz1, Victor Zeng1, Nicolas Raymond1, Jean Miewald3, Deborah Montrose3, Matcheri Keshavan4.   

Abstract

The thalamus, amygdala, and hippocampus play important pathophysiologic roles in psychosis. Few studies have prospectively examined subcortical nuclei in relation to predicting clinical outcomes after a first-episode of psychosis (FEP). Here, we examined volumetric differences and trajectories among subcortical nuclei in FEP patients and their associations with illness severity. Clinical and brain volume measures were collected using a 1.5T MRI scanner and processed using FreeSurfer 6.0 from a prospective study of antipsychotic-naïve FEP patients of FEP-schizophrenia (FEP-SZ) (baseline, n = 38; follow-up, n = 17), FEP non-schizophrenia (FEP-NSZ) (baseline, n = 23; follow-up, n = 13), and healthy controls (HCs) (baseline, n = 47; follow-up, n = 29). Compared to FEP-NSZ and HCs, FEP-SZ had significantly smaller thalamic anterior nuclei volume at baseline. Longitudinally, FEP-SZ showed a positive rate of change in the amygdala compared to controls or FEP-NSZ, as well as in the basal, central and accessory basal nuclei compared to FEP-NSZ. Enlargement in the thalamic anterior nuclei predicted a worsening in overall psychosis symptoms. Baseline thalamic anterior nuclei alterations further specify key subcortical regions associated with FEP-SZ pathophysiology. Longitudinally, anterior nuclei volume enlargement may signal symptomatic worsening. The amygdala and thalamus structures may show diagnostic differences between schizophrenia and non-schizophrenia psychoses, while the thalamus changes may reflect disease or treatment related changes in clinical outcome.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Amygdala; Annualized rate of change; First episode psychosis; Hippocampus; Thalamus

Mesh:

Year:  2021        PMID: 33484937      PMCID: PMC7904670          DOI: 10.1016/j.pscychresns.2021.111249

Source DB:  PubMed          Journal:  Psychiatry Res Neuroimaging        ISSN: 0925-4927            Impact factor:   2.376


  77 in total

1.  Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin.

Authors:  Sarah M Clinton; Hisham M Ibrahim; Kirk A Frey; Kenneth L Davis; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Am J Psychiatry       Date:  2005-10       Impact factor: 18.112

Review 2.  Thalamus-related anomalies as candidate mechanism-based biomarkers for psychosis.

Authors:  Pascal Steullet
Journal:  Schizophr Res       Date:  2019-05-27       Impact factor: 4.939

3.  In vivo hippocampal subfield volumes in schizophrenia and bipolar disorder.

Authors:  Unn K Haukvik; Lars T Westlye; Lynn Mørch-Johnsen; Kjetil N Jørgensen; Elisabeth H Lange; Anders M Dale; Ingrid Melle; Ole A Andreassen; Ingrid Agartz
Journal:  Biol Psychiatry       Date:  2014-07-03       Impact factor: 13.382

4.  High-resolution magnetic resonance imaging reveals nuclei of the human amygdala: manual segmentation to automatic atlas.

Authors:  Z M Saygin; D Kliemann; J E Iglesias; A J W van der Kouwe; E Boyd; M Reuter; A Stevens; K Van Leemput; A McKee; M P Frosch; B Fischl; J C Augustinack
Journal:  Neuroimage       Date:  2017-05-04       Impact factor: 6.556

Review 5.  GABAergic mechanisms of hippocampal hyperactivity in schizophrenia.

Authors:  Stephan Heckers; Christine Konradi
Journal:  Schizophr Res       Date:  2014-10-18       Impact factor: 4.939

6.  Medial temporal lobe in childhood-onset schizophrenia.

Authors:  J G Levitt; R E Blanton; R Caplan; R Asarnow; D Guthrie; A W Toga; L Capetillo-Cunliffe; J T McCracken
Journal:  Psychiatry Res       Date:  2001-11-05       Impact factor: 3.222

7.  Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls.

Authors:  Henning Witthaus; Christian Kaufmann; Georg Bohner; Seza Ozgürdal; Yehonala Gudlowski; Jürgen Gallinat; Stephan Ruhrmann; Martin Brüne; Andreas Heinz; Randolf Klingebiel; Georg Juckel
Journal:  Psychiatry Res       Date:  2009-07-17       Impact factor: 3.222

Review 8.  Targeting sleep oscillations to improve memory in schizophrenia.

Authors:  Dara S Manoach; Dimitrios Mylonas; Bryan Baxter
Journal:  Schizophr Res       Date:  2020-01-31       Impact factor: 4.939

9.  Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk.

Authors:  Tyrone D Cannon; Yoonho Chung; George He; Daqiang Sun; Aron Jacobson; Theo G M van Erp; Sarah McEwen; Jean Addington; Carrie E Bearden; Kristin Cadenhead; Barbara Cornblatt; Daniel H Mathalon; Thomas McGlashan; Diana Perkins; Clark Jeffries; Larry J Seidman; Ming Tsuang; Elaine Walker; Scott W Woods; Robert Heinssen
Journal:  Biol Psychiatry       Date:  2014-06-12       Impact factor: 13.382

10.  RNA-seq analysis of amygdala tissue reveals characteristic expression profiles in schizophrenia.

Authors:  X Chang; Y Liu; C-G Hahn; R E Gur; P M A Sleiman; H Hakonarson
Journal:  Transl Psychiatry       Date:  2017-08-15       Impact factor: 6.222

View more
  2 in total

1.  Adverse childhood experiences associate with early post-trauma thalamus and thalamic nuclei volumes and PTSD development in adulthood.

Authors:  Hong Xie; Nickelas Huffman; Chia-Hao Shih; Andrew S Cotton; Mark Buehler; Kristopher R Brickman; John T Wall; Xin Wang
Journal:  Psychiatry Res Neuroimaging       Date:  2021-11-26       Impact factor: 2.376

2.  Inflammatory Subtypes in Antipsychotic-Naïve First-Episode Schizophrenia are Associated with Altered Brain Morphology and Topological Organization.

Authors:  Dung Hoang; Yanxun Xu; Olivia Lutz; Deepthi Bannai; Victor Zeng; Jeffrey R Bishop; Matcheri Keshavan; Paulo Lizano
Journal:  Brain Behav Immun       Date:  2021-12-04       Impact factor: 7.217

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.